Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease

Cancer Medicine

Volumn 3, Issue 6, 2014, Pages 1615-1628

  Joshi, Bharat H ^a   Leland, Pamela ^a   Lababidi, Samir ^b   Varrichio, Frederick ^b   Puri, Raj K ^a  

^a Center for Biologics Evaluation and Research   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Biomarker; Bladder cancer associated protein; Grade and clinical stage; IL 4R ; Tumor aggressiveness

Indexed keywords

INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; MESSENGER RNA; IL4R PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR BIOPSY; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ADULT; AGED; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; FEMALE; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84990924522     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.330     Document Type: Article

References (50)

1. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9-29.
2. Dinney, C. P., D. J. McConkey, R. E. Millikan, X. Wu, M. Bar-Eli, L. Adam, et al. 2004. Focus on bladder cancer. Cancer Cell 6:111-116.
3. Burt, B. M., S. J. Rodig, T. R. Tilleman, A. W. Elbardissi, R. Bueno, and D. J. Sugarbaker. 2011. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 117:5234-5244.
4. Chapoval, S., P. Dasgupta, N. J. Dorsey, and A. D. Keegan. 2010. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J. Leukoc. Biol. 87:1011-1018.
5. Toomer, K. H., and Z. Chen. 2014. Autoimmunity as a double agent in tumor killing and cancer promotion. Front. Immunol. 5:116.
6. Kemp, R. A., and F. Ronchese. 2001. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J. Immunol. 167:6497-6502.
7. Stremmel, C., E. A. Greenfield, E. Howard, G. J. Freeman, and V. K. Kuchroo. 1999. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J. Exp. Med. 189:919-930.
8. Koller, F. L., D. G. Hwang, E. A. Dozier, and B. Fingleton. 2010. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis 31:1010-1017.
9. Prokopchuk, O., Y. Liu, D. Henne-Bruns, and M. Kornmann. 2005. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br. J. Cancer 92:921-928.
10. Obiri, N. I., G. G. Hillman, G. P. Haas, S. Sud, and R. K. Puri. 1993. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest. 91:88-93.
11. Toi, M., R. Bicknell, and A. L. Harris. 1992. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 52:275-279.
12. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, et al. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713-716.
13. Hosoyama, T., M. I. Aslam, J. Abraham, S. I. Prajapati, K. Nishijo, J. E. Michalek, et al. 2011. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clin. Cancer Res. 17:2757-2766.
14. Husain, S. R., R. J. Kreitman, I. Pastan, and R. K. Puri. 1999. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat. Med. 5:817-822.
15. Joshi, B. H., P. Leland, A. Asher, R. A. Prayson, F. Varricchio, and R. K. Puri. 2001. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res. 61:8058-8061.
16. Kawakami, K., P. Leland, and R. K. Puri. 2000. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res. 60:2981-2987.
17. Shimamura, T., R. E. Royal, M. Kioi, A. Nakajima, S. R. Husain, and R. K. Puri. 2007. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res. 67:9903-9912.
18. Husain, S. R., P. Gill, R. J. Kreitman, I. Pastan, and R. K. Puri. 1997. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin. Mol. Med. 3:327-338.
19. Puri, R. K. 1995. Structure and Function of Interleukin-4 and its Receptors. Pp. 143-186 in R. Kurzrock and M. Talpaz, eds. Cytokines: Interleukins and Their Receptors. Kluwer Academic Publishers, Norwell, MA.
20. Murata, T., J. Taguchi, and R. K. Puri. 1998. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood 91:3884-3891.
21. Puri, S., B. H. Joshi, C. Sarkar, A. K. Mahapatra, E. Hussain, and S. Sinha. 2005. Expression and structure of interleukin 4 receptors in primary meningeal tumors. Cancer 103:2132-2142.
22. Murata, T., J. Taguchi, R. K. Puri, and H. Mohri. 1999. Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system. Int. J. Hematol. 69:13-20.
23. Agresti, A., and Y. Min. 2002. Unconditional small-sample confidence intervals for the odds ratio. Biostatistics 3:379-386.
24. Corcoran, C. D., and C. R. Mehta. 2002. Exact level and power of permutation, bootstrap and asymptotic tests of trend. J. Mod. Appl. Stat. Meth. 1: 42-51.
25. Hosmer, D. W., and S. Lemeshow. 2000. Applied Logistic Regression. 2 edn. John Wiley & Sons, Inc, Hoboken, NJ.
26. Kawakami, M., K. Kawakami, and R. K. Puri. 2003. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J. Neurooncol. 65:15-25.
27. Puri, R. K., P. Leland, N. I. Obiri, S.R. Husain, J. Mule, I. Pastan, et al. 1996. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Cell. Immunol. 171:80-86.
28. Kioi, M., S. Takahashi, M. Kawakami, K. Kawakami, R. J. Kreitman, and R. K. Puri. 2005. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res. 65:8388-8396.
29. Rand, R. W., R. J. Kreitman, N. Patronas, F. Varricchio, I. Pastan, and R. K. Puri. 2000. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 6:2157-2165.
30. Weber, F., A. Asher, R. Bucholz, M. Berger, M. Prados, S. Chang, et al. 2003. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J. Neurooncol. 64:125-137.
31. Garland, L., B. Gitlitz, S. Ebbinghaus, H. Pan, H. de Haan, R. K. Puri, et al. 2005. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J. Immunother. 28:376-381.
32. Cancer Genome Atlas Research Network. 2014. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315-322.
33. Forbes, S. A., N. Bindal, S. Bamford, C. Cole, C. Y. Kok, D. Beare, et al. 2011. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 39:D945-D950.
34. Fang, Z. Q., W. D. Zang, R. Chen, B.W. Ye, X. W. Wang, S. H. Yi, et al. 2013. Gene expression profile and enrichment pathways in different stages of bladder cancer. Genet. Mol. Res. 12:1479-1489.
35. Li, Z., L. Chen, and Z. Qin. 2009. Paradoxical roles of IL-4 in tumor immunity. Cell. Mol. Immunol. 6:415-422.
36. Li, Z., J. Jiang, Z. Wang, J. Zhang, M. Xiao, C. Wang, et al. 2008. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res. 68:8687-8694.
37. Tepper, R. I., D. A. Levinson, B. Z. Stanger, J. Campos-Torres, A. K. Abbas, and P. Leder. 1990. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 62:457-467.
38. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc. Natl. Acad. Sci. USA 90:2774-2778.
39. Todaro, M., M. P. Alea, A. B. Di Stefano, P. Cammareri, L. Vermeulen, F. Iovino, et al. 2007. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1:389-402.
40. DeNardo, D. G., J. B. Barreto, P. Andreu, L. Vasquez, D. Tawfik, N. Kolhatkar, et al. 2009. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91-102.
41. Kobayashi, M., H. Kobayashi, R. B. Pollard, and F. Suzuki. 1998. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J. Immunol. 160:5869-5873.
42. Shurin, M. R., L. Lu, P. Kalinski, A. M. Stewart-Akers, and M. T. Lotze. 1999. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol. 21:339-359.
43. De Monte, L., M. Reni, E. Tassi, D. Clavenna, I. Papa, H. Recalde, et al. 2011. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208:469-478.
44. Asselin-Paturel, C., H. Echchakir, G. Carayol, F. Gay, P. Opolon, D. Grunewald, et al. 1998. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer 77:7-12.
45. Nakagomi, H., P. Pisa, E. K. Pisa, Y. Yamamoto, E. Halapi, K. Backlin, et al. 1995. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer 63:366-371.
46. Roussel, E., M. C. Gingras, E. A. Grimm, J. M. Bruner, and R. P. Moser. 1996. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin. Exp. Immunol. 105:344-352.
47. Burt, B. M., A. Bader, D. Winter, S. J. Rodig, R. Bueno, and D. J. Sugarbaker. 2012. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation. Clin. Cancer Res. 18:1568-1577.
48. Zelba, H., B. Weide, A. Martens, E. Derhovanessian, J. Kini Bailur, C. Kyzirakos, et al. 2014. Circulating CD4+ T-cells that produce IL-4 or IL-17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of stage IV melanoma patients. Clin. Cancer Res. 20:4390-4399.
49. Whitehead, R. P., J. M. Unger, J. W. Goodwin, M. J. Walker, J. A. Thompson, L. E. Flaherty, et al. 1998. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J. Immunother. 21:440-446.
50. Volonte, A., T. Di Tomaso, M. Spinelli, M. Todaro, F. Sanvito, L. Albarello, et al. 2014. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J. Immunol. 192:523-532.